insiderwall
Menu
SuperinvestorInsider
NovoCure Ltd. NVCR

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Novocure Ltd. is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), an innovative, non-invasive cancer therapy using alternating electric fields tuned to specific frequencies to disrupt cancer cell division while sparing healthy tissue. Its commercialized products, including Op

SectorHealthcare
ExchangeNASDAQ
IndustryMedical Devices
CountrySwitzerland
Employees1,605
TickerNVCR

Statistics

Market Cap$2.05B
Revenue (TTM)$655.4M
Net Income-$136.2M
Net Margin-20.8%
EPS$-1.22
P/E-14.72
P/S3.04
P/B6.20
EV/EBITDA-10.42
ROE-50.0%
Dividend Yield
Price$17.72

Data: Twelve Data · Revenue = mcap / P/S